GT Medical Technologies
GT Medical Technologies develops GammaTile, an FDA-cleared bioresorbable collagen implant embedded with cesium-131 radiation seeds for targeted brain tumor radiation therapy at the time of resection. The company sells directly to U.S. hospitals and cancer centers.
- Company typePrivate
- Founded2017
- HeadquartersTempe, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What GT Medical Technologies does
GT Medical Technologies, Inc. is a Tempe, Arizona-based, privately held medical device company founded in 2017 by a group of brain tumor specialists (David G. Brachman, Heyoung McBride, Peter Nakaji, Emad Youssef, Theresa Thomas) to address the treatment gap between brain tumor resection surgery and post-operative external beam radiation. The company's sole commercial product, GammaTile, is an FDA-cleared, bioresorbable collagen tile embedded with four cesium-131 radiation seeds offset 3mm from the tile surface; the implant is placed at the time of craniotomy and delivers approximately 88-90% of its therapeutic dose within 30 days, eliminating the typical 2-8 week wait between surgery and adjuvant radiation. GammaTile is cleared for both newly diagnosed malignant intracranial neoplasms and recurrent intracranial neoplasms and is supported by a peer-reviewed evidence base that includes the ROADS Phase 3 randomized trial (presented at ASCO 2026 with superior local control and survival outcomes versus standard stereotactic radiotherapy), the GESTALT and BRIDGES glioblastoma trials, and a real-world registry study reporting 92.3% local control at 12 months and a 9.8% Grade 3 toxicity rate with no radiation necrosis.
GT Medical operates an enterprise direct-sales model, selling GammaTile through a proprietary ordering portal (orders.gammatile.com) and field representatives to hospitals and cancer centers across the United States. Revenue is one-time per procedure on a quote-based pricing model, with a formal Commitment Pledge that waives charges for recurrent-tumor cases canceled intraoperatively if pathology reveals only necrotic tissue. The company has built a network of 20+ Centers of Excellence anchored by MD Anderson, Memorial Sloan Kettering, USC Brain Tumor Center, AdventHealth Orlando, Piedmont Atlanta, Miami Cancer Institute, VCU Massey and Mayfield Brain and Spine, complemented by a full suite of medical physics and reimbursement toolkits (Cavity Surface Area Calculator, Medical Physics Toolkit, RAM License Toolkit, Coding and Reimbursement Toolkit).
The company has raised approximately $263 million in equity across nine rounds (most recently a $100 million Series E in June 2026 led by Viking Global Investors) plus a $35 million debt facility from Horizon Technology Finance in 2024, and it acquired IsoRay and its Cesium-131 isotope business in December 2023 to vertically integrate its radioactive source supply chain. Leadership comprises an experienced medtech executive bench (CEO Per Langoe, CMO Michael Garcia, CSO/CFO James Leech, COO Ole Mikkelsen, CMO Richard Low, CCO Jeff Lewis) and operates a 101-250 person organization from its Tempe headquarters.
GT Medical Technologies firmographics
Firmographics- Name
- GT Medical Technologies
- Legal name
- GT Medical Technologies, Inc.
- Website
- https://gammatile.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- GT Medical Technologies develops GammaTile, an FDA-cleared bioresorbable collagen implant embedded with cesium-131 radiation seeds for targeted brain tumor radiation therapy at the time of resection. The company sells directly to U.S. hospitals and cancer centers.
- Ownership category
- akta.pro rank
GT Medical Technologies industry classification
Industry- Product category
- Radiation Therapy Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Irradiation Apparatus Manufacturing (334517), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Radiation Oncology (HLAKAFAC)
- akta.pro secondary industry
- Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)
Keywords
Where GT Medical Technologies is headquartered
LocationHeadquarters
- HQ city
- Tempe
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
GT Medical Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- GammaTile Device Sales: GT Medical Technologies generates revenue through the sale of GammaTile radiation therapy devices to hospitals and treatment centers. The company sells directly to healthcare providers who order tiles through the GammaTile ordering portal for use during brain tumor resection surgeries. Revenue is one-time per procedure, with unused tiles eligible for return.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Quote-based pricing for GammaTile devices |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
GT Medical Technologies product offering
Product offeringCore offering
GT Medical Technologies manufactures and sells GammaTile, an FDA-cleared bioresorbable collagen tile embedded with four cesium-131 radiation seeds, implanted at the time of brain tumor resection surgery to deliver immediate, targeted radiation therapy to the tumor cavity. The company supports hospitals and cancer centers with ordering infrastructure, medical physics tools, coding and reimbursement resources, Centers of Excellence program, and clinical trial participation.
Product overview
GT Medical Technologies offers GammaTile, a tile-based radiation therapy (TBRT) system consisting of the FDA-cleared GammaTile bioresorbable collagen implant embedded with cesium-131 radiation seeds, along with supporting medical physics tools (Cavity Surface Area Calculator, Lookup Table, Medical Physics Toolkit, RAM License Toolkit), clinical programs (ROADS Phase 3 trial, GESTALT trial, GammaTile Registry), and commercial services (Coding and Reimbursement Toolkit, Commitment Pledge, Centers of Excellence program). The core GammaTile product is implanted at the time of brain tumor resection surgery to deliver immediate, targeted radiation therapy.
Differentiator
Problem solved
Functional benefit
Products and services
- GammaTile FDA-cleared bioresorbable collagen tile embedded with cesium-131 radiation seeds, implanted at the time of brain tumor resection surgery to deliver immediate, targeted radiation therapy to remaining tumor cells. Designed for patients with newly diagnosed malignant intracranial neoplasms and recurrent intracranial neoplasms, including glioblastoma, brain metastases, and meningiomas.
- GammaTile Commitment Pledge Product policy and risk-sharing service for healthcare providers that waives the GammaTile charge when procedures are canceled because intraoperative pathology shows only necrotic tissue, reducing financial exposure for hospitals performing recurrent brain tumor resections.
- ROADS Phase 3 Clinical Trial (NCT04365374) Sponsored randomized Phase 3 clinical trial comparing GammaTile plus resection versus resection plus post-operative stereotactic radiotherapy for newly diagnosed brain metastases. Generates clinical evidence supporting adoption and is offered through participating medical centers including MD Anderson.
- GammaTile Centers of Excellence Program Designated network of medical institutions recognized for exceptional expertise in GammaTile procedures, offering proctoring support, patient education, and clinical outcomes research. Includes MD Anderson, USC Brain Tumor Center, AdventHealth Orlando, Piedmont, Mayfield Brain & Spine, Miami Cancer Institute, and VCU Massey Cancer Center.
Quantifiable outcome
- 92.3% local tumor control at 12 months in newly diagnosed brain metastases patients
- +5 more outcomes
Companies that use GT Medical Technologies
Customer profileNamed customers8 records
Segments2 records
Ideal customer profiles1 record
GT Medical Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
GT Medical Technologies partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- MD Anderson Cancer CentercoreLead institution for the ROADS (Radiation Options After Deduced Surgery) Phase 3 randomized clinical trial comparing GammaTile to standard stereotactic radiotherapy for newly diagnosed brain metastases. Dr. Weinberg presented final results at ASCO 2026.
- Memorial Sloan Kettering Cancer CentercoreSponsor and lead institution for the Phase II randomized clinical trial studying intracavity carrier-embedded Cs-131 brachytherapy for recurrent brain metastases. The trial compares GammaTile plus surgery versus surgery alone.
- Various Medical Institutions (Centers of Excellence)coreNetwork of 20+ GammaTile Centers of Excellence including USC Brain Tumor Center, AdventHealth Orlando, Piedmont, Mayfield Brain & Spine, Miami Cancer Institute, and others. These institutions demonstrate exceptional expertise in GammaTile procedures and contribute to patient education and clinical outcomes research.
- Finn PartnersminorPublic relations firm handling media inquiries for GammaTile and the ROADS clinical trial. Contact: [email protected]
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
GT Medical Technologies competitors and assessment
Company assessmentBroad incumbents
- IBA (Ion Beam Applications): Proton therapy equipment manufacturer and radioisotope producer; competes with GammaTile in brain tumor radiation oncology and shares exposure to the radioisotope supply chain through its radiopharmaceuticals business.
- Elekta: Global leader in radiation therapy and radiosurgery hardware (including Leksell Gamma Knife) widely used for brain tumor treatment; competes with GammaTile in the post-operative brain metastases setting where Elekta's linear accelerator-based systems and Gamma Knife remain the standard of care compared against GammaTile in the ROADS trial.
- Varian Medical Systems (Siemens Healthineers): Dominant external beam radiation therapy and stereotactic radiosurgery platform provider (TrueBeam, Edge); competes with GammaTile for brain tumor treatment dollars and serves the same radiation oncology departments targeted by GT Medical's field sales force.
- BTG (Boston Scientific): Through its BTG acquisition, Boston Scientific markets a portfolio of brachytherapy seeds (including I-125-based systems historically used in brain tumors); competes with GammaTile's Cs-131 brachytherapy approach and shares the implantable radiation oncology category.
- Accuray: Maker of CyberKnife and TomoTherapy stereotactic radiosurgery systems used for brain metastases and other intracranial indications; competes against GammaTile in the post-operative radiation setting referenced in the ROADS trial comparator arm.
Direct peers
- Novocure: Commercial-stage oncology company with Optune (TTFields), an FDA-approved therapy for newly diagnosed and recurrent glioblastoma; directly competes with GammaTile in the recurrent glioblastoma indication and addresses the same neuro-oncology patient population.
- IsoRay Medical: Historical direct competitor and brachytherapy isotope producer using Cesium-131 seeds; GT Medical acquired IsoRay in December 2023 to vertically integrate the Cs-131 supply chain that powers GammaTile, making IsoRay now an in-house asset rather than an independent competitor.
- Theragenics: Specialized brachytherapy seed manufacturer with a portfolio that has historically included brain tumor applications; competes directly with GammaTile in implantable radioactive seed therapy and shares the same clinical and regulatory pathway.
Emerging players
- ViewRay: MR-guided radiation therapy systems used in oncology, including intracranial applications; represents an emerging technology alternative to both traditional external beam radiation and implantable brachytherapy approaches for brain tumors.
Regional players
- Mevion Medical Systems: Compact proton therapy system manufacturer; competes with GammaTile as an alternative radiation modality for intracranial and pediatric brain tumors, primarily in academic and specialty oncology centers in North America.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
GT Medical Technologies social profiles
Digital presenceGT Medical Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
GT Medical Technologies leadership team
Management profileNumber of profiles
Profiles13 records
GT Medical Technologies funding detail
Funding detailFunding overview
Funding rounds9 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GT Medical Technologies M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GT Medical Technologies
What does GT Medical Technologies do?
GT Medical Technologies manufactures and sells GammaTile, an FDA-cleared bioresorbable collagen tile embedded with four cesium-131 radiation seeds, implanted at the time of brain tumor resection surgery to deliver immediate, targeted radiation therapy to the tumor cavity. The company supports hospitals and cancer centers with ordering infrastructure, medical physics tools, coding and reimbursement resources, Centers of Excellence program, and clinical trial participation.
Is GT Medical Technologies a public or private company?
GT Medical Technologies is a private company. It is classified as venture growth investor backed and is currently operating.
When was GT Medical Technologies founded?
GT Medical Technologies was founded in 2017. It employs 101 to 250 people.
Where is GT Medical Technologies based?
GT Medical Technologies is headquartered in Tempe, United States, in the North America region.
How does GT Medical Technologies make money?
One revenue line is on record: gammaTile Device Sales.
Who are GT Medical Technologies's main competitors?
Broad incumbents on record are IBA (Ion Beam Applications), Elekta, Varian Medical Systems (Siemens Healthineers), BTG (Boston Scientific) and Accuray. Direct peers are Novocure, IsoRay Medical and Theragenics. ViewRay is listed as an emerging player. Mevion Medical Systems is listed as a regional player.
Does GT Medical Technologies have an API?
No public API is recorded for GT Medical Technologies.
What industry is GT Medical Technologies in?
GT Medical Technologies's product category is Radiation Therapy Medical Devices. Its primary akta.pro industry code is HLAKAFAC, Radiation Oncology, with a secondary code of HLAHAEAD, Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts). Its NAICS code is 339112 and its SIC code is 3841.